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Abstract 31 
Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is used to suppress 32 
graft-versus-host disease in patients undergoing hematopoietic stem cell transplantation (HCT). The 33 
purpose of this study was to construct a population pharmacokinetic and pharmacodynamic model in 34 
HCT patients for individualized MPA therapy. Blood samples were obtained from 49 HCT patients after 35 
starting MMF therapy. Population pharmacokinetic and pharmacodynamic parameters were obtained 36 
using the program NONMEM. MPA was described via a 1-compartment model with a first order 37 
elimination, and 30.9% of MPA glucuronide (MPAG) was found in the enterohepatic circulation. 38 
Inosine-5’-monophosphate dehydrogenase (IMPDH) activity was modeled as a maximal inhibitory model 39 
with a half-maximal inhibitory concentration (IC50) of 3.59 µg/mL against MPA concentrations. 40 
Simulations based on the obtained pharmacokinetic and pharmacodynamic parameters revealed that 41 
decreased creatinine clearance increases the MPAG concentration followed by an increased MPA 42 
concentration; therefore, IMPDH activity decreases. Diarrhea decreases the enterohepatic circulation of 43 
MPAG and consequently reduces MPA concentration. The IC50 for MPA exhibited a positive association 44 
with C-reactive protein. Dosage adjustment based on plasma MPA concentration is required especially 45 
for patients with renal dysfunction and/or diarrhea.   46 
 4 
Introduction 47 
Mycophenolate mofetil (MMF) is clinically used to suppress graft-versus-host disease (GVHD) in 48 
patients undergoing hematopoietic stem cell transplantation (HCT) and acute rejection after solid organ 49 
transplantation1,2. Mycophenolic acid (MPA), an active form of MMF, is metabolized by 50 
glucuronosyltransferases in the liver. MPA glucuronide (MPAG) and MPA acyl glucuronide (AcMPAG) 51 
are primarily produced by UGT1A9 and 2B7, respectively 3. While MPAG is an inactive metabolite, 52 
AcMPAG exhibits pharmacological activity in vitro and is potentially responsible for the toxicity of MPA 53 
4. The majority of MPA metabolites are eliminated via the urine and partial elimination also occurs in the 54 
bile mediated by multidrug resistance associated protein 2 (MRP2) followed by the entero-hepatic 55 
recirculation 5. 56 
The pharmacokinetics (PK) of MPA exhibits a large inter- and intra-individual variability, and it is 57 
recommended that the area under the concentration-time curve (AUC) of MPA be monitored for 58 
individualized therapy in solid organ transplant recipients6, 7. Recently, Arai et al. 8 proposed that MPA 59 
drug monitoring was necessary for the effective prophylaxis of acute GVHD undergoing cord blood stem 60 
cell transplantation (CBT). However, information regarding the optimal dose of MMF or the target range 61 
for MPA concentrations in HCT patients is limited 9. 62 
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MPA selectively inhibits inosine-5’-monophosphate dehydrogenase (IMPDH) and suppresses the 63 
proliferation of B and T lymphocytes 10. IMPDH exists as two isoforms derived from different genes 11, 12, 64 
and recombinant proteins of IMPDH2 is 4.8-fold more sensitive to MPA than IMPDH113. The area under 65 
the effect curve (AUEC) of IMPDH activity on day 21 after HCT was reportedly associated with both 66 
non-relapse and overall mortality 14. Therefore, the measurement of IMPDH activity in peripheral blood 67 
mononuclear cells (PBMCs) in addition to monitoring the AUC of MPA is considered to be an effective 68 
predictor of the clinical outcome of MPA therapy.  69 
The PK of MPA is influenced by serum albumin, renal dysfunction, total bilirubin, age, 70 
co-administration with cyclosporine, and dose 15-19. In addition, the incidence of acute rejection in the first 71 
year post-transplantation was significantly lower in carriers of SNPs for IMPDH1 -106 G>A and 125 72 
G>A compared with the respective wild-type individuals20. The SNP for IMPDH2 3757 T>C was 73 
associated with a significantly higher IMPDH activity following the MMF intake, despite of no difference 74 
in the MPA exposure between groups21. The SNP for MRP2 -24C>T was associated with a significantly 75 
higher dose-corrected MPA trough levels at later time points after transplantation22. The SNP for 76 
UGT2B7 -842G>A resulted in a significantly higher AUC of AcMPAG at 1 and 3 months 77 
post-transplantation in patients with renal transplantation23.  78 
 6 
In this study, the effects of the patient characteristics including previously proven genetic 79 
polymorphisms were examined using a population PK and pharmacodynamics (PD) analysis. Effects of 80 
covariates were quantitatively evaluated by the simulation to examine the clinical significance of these 81 
covariates.  82 
 83 
Subjects and Methods 84 
Study design 85 
A total of 49 adult Japanese HCT patients between March 2013 and August 2016 were included in 86 
the study. Acute GVHD prophylaxis comprised tacrolimus (PrografTM, Astellas Pharma Inc., Tokyo, 87 
Japan) and MMF (CellceptTM, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) in CBT, plus short-term 88 
methotrexate (MethotrexateTM, Pfizer Japan Inc., Tokyo, Japan) in bone marrow transplant (BMT) or 89 
peripheral blood stem cell transplantation (PBT). MMF was orally administered at 10 mg/kg every 8 h 90 
(30 mg/kg/day), and was initiated on day −1 after CBT or on day 7 after BMT and PBT, except in one 91 
patient administered 15 mg/kg every 12 h. No potentially interacting drugs including cyclosporine or 92 
foods with MPA were co-administered. 93 
Pre-transplant recipient DNA was used to determine UGT2B7 −842C>T (rs7439366) and MRP2 94 
−24C>T (rs717620) genotypes. Approximately five weeks after MMF administration commenced, 95 
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post-transplant donor DNA as well as pre-transplant recipient DNA were used to determine IMPDH1 −96 
106G>A (rs2278294), IMPDH1 125G>A (rs2278293), and IMPDH2 3757T>C (rs11706052) genotypes. 97 
Blood samples were collected immediately before, 1, 2, 4, and 8 h after the first and third weeks after 98 
MMF administration commenced, plus blood sampling at 12 h after MMF administration in one patient 99 
administered 15 mg/kg every 12 h. This clinical study was approved by the Ethics Committee of Kyoto 100 
University Graduate School and Faculty of Medicine and Kyoto University Hospital. Written informed 101 
consent was obtained from all patients included in the study. 102 
 103 
Analytical methods 104 
Total plasma concentrations of MPA, MPAG, and AcMPAG were analyzed using LC-MS/MS 105 
according to the previously reported method 24. The lower limits of quantification (LLOQ) were 0.05, 0.2, 106 
and 0.02 µg/mL for MPA, MPAG, and AcMPAG, respectively. PBMC samples were used to measure the 107 
IMPDH activity according to the previous method 24. The IMPDH activity was calculated based on the 108 
XMP produced, which was normalized to the intracellular AMP. The LLOQ were 50 nM for both XMP 109 
and AMP. The data for AMP under the LLOQ were excluded from the analysis due to extremely low 110 
white blood cell counts after the transplantation. 111 
 112 
Population PK/PD analysis 113 
 8 
A population PK analysis was conducted using NONMEM. The overview of the basic PK/PD 114 
model for MPA is shown in Fig. 1. Since only the oral data were available, the relative bioavailability (F) 115 
of MPA was assumed to be 1. The model was parameterized using clearances for MPA, MPAG, and 116 
AcMPAG (CLMPA, CLMPAG, and CLAcMPAG), as well as the volume of distribution for MPA, MPAG, and 117 
AcMPAG (VMPA, VMPAG, and VAcMPAG). It was assumed that MPA was metabolized to MPAG and 118 
AcMPAG by a first-order process, in which 99 % and 1 % of MPA was converted to MPAG and 119 
AcMPAG, respectively, because the ratio of AUC0–8 for MPAG to AcMPAG was approximately 99:1 in 120 
this study. The enterohepatic circulation (EHC) was tested as a first-order process (KEHC) from the central 121 
compartment of each metabolite to the gastrointestinal tract. For the comparison, 2-compartment model 122 
with EHC, and the lag time and the transit compartment models in the absorption process were tested 25. 123 
Additionally, EHC modeling by presuming a hypothetical gall bladder compartment was tested 26, 27.  124 
Interindividual and interoccasion variability (IIV and IOV) in the PK/PD parameters were 125 
modeled using an exponential error model 28. The estimation for the IOV was as follows: occasions 1 and 126 
2 pertained to one and three weeks after MMF administration commenced, respectively. The influence of 127 
each covariate on the population mean parameters was evaluated by the stepwise forward inclusion and 128 
backward elimination method, and significance levels were 1 % and 0.1 % (6.63 and 10.8 with freedom 129 
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of 1 assuming a chi-square distribution), respectively. The tested covariates for the PK parameters 130 
included body weight, gender, stem cell source, age, aspartate aminotransferase, serum albumin, total 131 
bilirubin, creatinine clearance (CLCR), dose of MMF, diarrhea, and investigated genotypes for MRP2 and 132 
UGT2B7 of recipient. Diarrhea was defined as the occurrence of loose, muddy or watery stool, or more 133 
than five times per a day of fecal frequency in case of not recording the fecal condition.  134 
Continuous variables were normalized by each population median using the following power 135 
function model: 136 
θi  =  θpop  ×  ( COViCOVmed)θcov                                        137 
(1) 138 
where θi is the individual model-predicted PK parameter (e.g. CLMPA) for an individual with covariate 139 
value of COVi. θpop represents the population mean for the parameter θ, COVmed represents the population 140 
median of the covariate, and θcov represents the covariate effect. For dichotomous variables, the value of 141 
COVi is typically set to 0 for the normal classification and 1 for the other classifications in each 142 
individual as follows: 143 
 θi  =  θpop  ×  θcovCOVi       (2) 144 
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After the final population PK model was obtained, the relationship between the MPA 145 
concentrations and IMPDH activity was explored graphically and modeled using a direct sigmoid 146 
inhibitory maximum effect model as followed: 147 
   E =  E0 ×  (1 − CMPAγIC50,MPAγ +CMPAγ )     (3) 148 
where E0, IC50,MPA, and γ represent baseline of IMPDH activity, half-maximal inhibitory MPA 149 
concentration, and the Hill coefficient to be estimated 29, and CMPA represents the MPA concentration. To 150 
investigate the effect of the AcMPAG concentration on IMPDH activity, an additional inhibitory effect 151 
model was tested 30. The tested covariates for the PD parameters included the stem cell source, 152 
reduced-intensity conditioning, gender, age, serum albumin, C-reactive protein (CRP), and investigated 153 
genotypes (IMPDH1 and 2) of donor or recipient. In the value of CRP was under the LLOQ (<0.2 154 
mg/mL), this value was converted to 0.1 due to the difficulty of the calculation. Goodness-of-fit and 155 
prediction-corrected visual predictive check plots were used for internal validation 31. For 156 
prediction-corrected visual predictive check plots, the final PK/PD model was used to simulate original 157 
data sets at 1000 times compared with the observed data. 158 
 159 
Simulation study 160 
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The effects of statistically significant covariates on the PK/PD of MPA were evaluated by the 161 
simulation using the final population parameters. The dose was fixed to 500 mg every 8 h for all 162 
simulations. In the simulation for the effect of each covariate, other covariates were fixed to the median 163 
value of each covariate and without diarrhea. The AUC0–8 or AUEC0–8 were calculated using the linear 164 
trapezoidal method. 165 
 166 
Results 167 
Patient characteristics 168 
The patient characteristics and the distribution of each genotype before and five weeks after the 169 
transplantation are summarized in Table 1. All of the observed genotype distributions were consistent 170 
with Hardy-Weinberg equilibrium. 171 
 172 
Population PK modeling 173 
In total, 522 concentration data for MPA, MPAG, and AcMPAG, respectively, were analyzed. Five 174 
samples with MPA concentrations under the LLOQ were replaced with half of the LLOQ 32, and included 175 
in the analysis. 2-compartment model improved the model fitting compared with 1-compartment model 176 
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without EHC. However, after an inclusion of EHC process, 2-compartment model did not improve the 177 
model fitting compared with 1-compartment model (∆OBJ = −8.12), and a terminal elimination rate 178 
constant was not correctly estimated. Therefore, the PK of MPA was finally described by 1-compartment 179 
model with first order absorption and elimination, and was affected by the EHC of MPAG. An inclusion 180 
of the absorption lag-time did not improve the model fitting. Transit compartment model was not adopted 181 
owing to the high computational intensity required, although the model fit was significantly improved. 182 
Although the inclusion of EHC of AcMPAG in the model brought a statistically significant model 183 
improvement, CLAcMPAG was not correctly estimated. Therefore, the model including the EHC of only 184 
MPAG was selected. EHC modeling by presuming a hypothetical gall bladder compartment did not 185 
improve the model fitting compared with first-order EHC model. The simultaneous inclusion of IOVs for 186 
Ka, F, KEHC, CLMPAG, and CLAcMPAG significantly improved the model fitting (∆OBJ = −721). The final 187 
PK parameters and its relative standard error (RSE) are presented in Table 2. Figure 2 shows the 188 
inter-occasional parameters for one and three weeks after MMF administration commenced. 189 
After the evaluation of each covariate, the serum albumin revealed a significant negative association 190 
with CLMPA and VMPA. CLCR exhibited a significant positive relationship with both CLMPAG and CLAcMPAG, 191 
and KEHC in the patients showing diarrhea was 0.375-fold lower than that without diarrhea (Table 2). An 192 
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inclusion of IIV was tested for all the MPA PK parameters and an exclusion of IIV was tested after 193 
inclusion of IOV. After all, IIVs on VMPA and F were retained in the final model, and shrinkage values of 194 
them were 27.6% and 16.8%, respectively. The ratio for the EHC of MPAG was estimated to be 30.9% 195 
(EHC (%) = KEHC/(KEHC + CLMPAG/VMPAG) × 100) in patients with CLCR of 112 mL/min without diarrhea.  196 
 197 
PD modeling 198 
A total of 460 IMPDH activity data from 49 patients were used for the PD model building following 199 
the PK modeling process. The 62 IMPDH activity data were excluded due to AMP under the LLOQ. The 200 
IMPDH activity was described with the inhibitory Emax model using the MPA concentrations. The Hill 201 
coefficient was fixed to 1 by the statistical selection (∆OBJ = −3.00). The additive inhibitory effect 202 
model for AcMPAG did not significantly improve the model fitting. An inclusion of IOV on E0 203 
significantly improved the model fitting (∆OBJ = −200). The value of IC50 for MPA revealed a positive 204 
association with CRP (∆OBJ = −11.4). No polymorphisms were identified as significant covariates in 205 
the PK/PD model. The final PD parameters with RSE are shown in Table 2. The IIV for IC50 was 81.2%, 206 
and its shrinkage was 29.7%. The goodness-of-fit and prediction-corrected visual predictive check 207 
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demonstrated that the population PK/PD model accurately predicted the observed MPA and its 208 
metabolites concentrations, as well as IMPDH activity (Figs. 3 and 4). 209 
 210 
Simulation study  211 
A total of 1,000 data sets in each group were simulated under the several renal functions with or 212 
without diarrhea (Fig. 5). The AUC0-8 of MPAG and AcMPAG significantly increased according to the 213 
decreased CLCR compared with those for 120 mL/min. The AUC0-8 of MPA also significantly increased 214 
according to the decreased CLCR. The AUEC0-8 of IMPDH significantly decreased from 339 to 215 215 
µmol·h·sec−1·mol AMP−1 with a decrease in CLCR from 120 to 10 mL/min; however, a large 216 
interindividual variability was noted. In addition, the diarrhea significantly decreased the AUC0-8 of both 217 
MPA and AcMPAG in every CLCR, but did not affect the AUC0-8 of MPAG. The AUEC0-8 of IMPDH 218 
with diarrhea was significantly higher than that without diarrhea in the case of CLCR under 60 mL/min. 219 
The AUC0-8 of MPA significantly decreased with a reduction in serum albumin, although the 220 
AUEC0–8 of IMPDH did not significantly change (Fig. 6). At a MPA concentration of 3.59 µg/mL, which 221 
is equal to the population mean of IC50 in the case of CRP of 1.2 mg/dL, the IMPDH activity is 1.34-fold 222 
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higher in patients with CRP of 10 mg/dL, compared with that for CRP of 1.2 mg/dL. The AUEC0-8 of 223 
IMPDH also significantly increases as the CRP rises. 224 
 225 
Discussion 226 
Patients undergoing HCT generally have intestinal mucosal damage due to a myeloablative or 227 
reduced intensity conditioning regimen prior to HCT 33. Indeed, MPA concentrations in HCT patients are 228 
generally lower than those of organ transplant patients despite an equivalent dose of MMF 34. In addition, 229 
leukopenia and co-administered antibiotics induce the destruction of intestinal flora, leading to diarrhea. 230 
The diarrhea decreased the reabsorption of MPA in the gastro-intestinal tract, and consequently decreased 231 
the MPA concentration. In this study, IMPDH activity in CLCR under 60 mL/min with diarrhea was 232 
significantly higher compared to those in the same CLCR without diarrhea in the same MPA dosing, 233 
secondary to the PK changes.  234 
In the early phase after transplantation, HCT patients suffer from renal impairment due to 235 
thrombotic microangiopathy, which is an adverse effect caused by calcineurin inhibitors and high-dose 236 
chemotherapy 35. Since MPA metabolites are excreted into the urine, the clearance of MPA metabolites 237 
have been reported to decrease in association with lower renal function 14, 36. In the simulation using the 238 
 16 
final PK/PD parameters, MPA concentration will be increased with a decreased CLCR, due to the 239 
enhanced EHC of MPAG. Moreover, the IMPDH activity in CLCR under 30 mL/min was significantly 240 
lower than that in 120 mL/min. Therefore, particular attention regarding extra-immunosuppression in 241 
response to MPA is needed for patients with severe renal dysfunction. 242 
The target range of MPA exposure may be influenced by changes in serum albumin, since the free 243 
fraction of MPA was 1–2% 37. In the PD analysis, we speculated that the serum albumin had a significant 244 
effect on the IC50 value of MPA due to the changed unbound fraction of MPA; however, we were unable 245 
to conclusively demonstrate this effect due to a large inter- and intra-individual variability in IMPDH 246 
activity. Therefore, changes in the serum albumin in clinical situations might not have a significant effect 247 
on IMPDH activity, although it can affect the PK of MPA.  248 
Interestingly, CRP exhibited a positive association with the IC50 for MPA. Patients undergoing HCT 249 
suffered from various symptoms caused by an infection and/or the excessive production of inflammatory 250 
cytokines on the days around the engraftment 38, 39. Indeed, the median of CRP in one week after starting 251 
the MMF therapy (3.0 mg/dL) was significantly higher than that in three weeks after the therapy (0.8 252 
mg/dL). Moreover, IMPDH1 is constitutively expressed in normal leukocytes, whereas IMPDH2 is 253 
up-regulated in neoplastic and replicating cells40, 41. These findings suggest the reasons why CRP 254 
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exhibited a positive association with the IC50 for MPA. Whether the elevated CRP value reflects infection 255 
or excessive production of inflammatory cytokines remains to be examined. 256 
The simultaneous inclusion of IIVs and IOVs for PK/PD parameters significantly improved the 257 
model fitting. HCT patients have single or multiple damages due to the conditioning regimen, infection or 258 
excessive production of inflammatory cytokines33, 38, 39, 42. In addition, the recovery rate of organic and 259 
hematopoietic functions following HCT showed a large variability. Therefore, the IIV and IOV in the 260 
PK/PD of MPA in HCT patients should be large. 261 
The present study included some limitations. The PK of MPA is usually expressed as 262 
2-compartment model, and/or sometimes includes more sophisticated models 26, 27. In this study, the 263 
model fitting was not improved by using any sophisticated models. The examined model largely depends 264 
on the experimental design, and we would like to pick up clinical significant covariates on the PK of 265 
MPA in a routine clinical care as shown in the previous our study 8. Additionally, although our population 266 
size was modest, the estimated parameters, such as the ratio of EHC of MPAG or the IC50 for MPA, were 267 
similar to those of previous reports 14. Therefore, the constructed PK/PD model for MPA was considered 268 
to be appropriate. The effects of covariates extracted in the present study should be examined by 269 
2-compartment model using more rich sampling data in a future.  270 
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In conclusion, we successfully constructed a population PK/PD model of MPA in patients 271 
undergoing HCT. Renal dysfunction, diarrhea, and CRP are clinically significant factors affecting the PD 272 
of MPA in the same dosing regimen. Dosage adjustment based on plasma MPA concentration is required 273 
especially for patients with renal dysfunction and/or diarrhea. 274 
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 Figure legends 397 
Fig. 1 Overview of the basic pharmacokinetic and pharmacodynamic model characterizing mycophenolic 398 
acid (MPA), MPA glucuronide (MPAG), MPA acylglucuronide (AcMPAG), and 399 
inosine-5’-monophosphate dehydrogenase (IMPDH). GI, gastrointestinal tract; Ka, first-order absorption 400 
rate constant; CLMPA, clearance of MPA; CLMPAG, clearance of MPAG; CLAcMPAG, clearance of 401 
AcMPAG; VMPA, volume of distribution of MPA; VMPAG, volume of distribution of MPAG; VAcMPAG, 402 
volume of distribution of AcMPAG; KEHC, first-order rate constant of enterohepatic circulation; FM1, 403 
fraction of MPA converted to MPAG. 404 
 405 
Fig. 2 Interoccasional pharmacokinetic and pharmacodynamic parameters between one and three weeks 406 
after initiation of mycophenolate mofetil (MMF) therapy. (A) The first-order absorption rate constant 407 
(Ka); (B) relative bioavailability (F); (C) clearance of MPAG (CLMPAG); (D) clearance of AcMPAG 408 
(CLAcMPAG); (E) first-order rate constant for the enterohepatic circulation (KEHC); (F) baseline IMPDH 409 
activity (E0).  410 
 411 
 28 
Fig. 3 Goodness-of-fit plots of the observed versus population predictions (A-D) or individual predictions 412 
(E-H) using the final model. (A and E) MPA concentrations; (B and F) MPAG concentrations; (C and G) 413 
AcMPAG concentrations; (D and H) IMPDH activity. Each dotted line denotes the line of identity. 414 
 415 
Fig. 4 Prediction corrected visual predictive check plots. All open circles represent the observed 416 
concentrations or IMPDH activities (prediction corrected). (A-D) one week after initiation of MMF 417 
therapy; (E-H) three weeks after initiation of MMF therapy. The solid line represents the median of the 418 
observed data. The dotted line represents the observed 5th and 95th percentiles. The shaded area denotes 419 
the simulation-based 95% confidence interval for the median or the 5th and 95th percentiles. 420 
 421 
Fig. 5 Simulation for the effects of creatinine clearance (CLCR) and diarrhea on the pharmacokinetics and 422 
pharmacodynamics of MPA in typical patients based on the final population model. (A) AUC0-8 of MPA; 423 
(B) AUC0-8 of MPAG; (C) AUC0-8 of AcMPAG; (D) AUEC0–8 of IMPDH activity. The dose of MMF 424 
was fixed to 500 mg every 8 h. Each box plot represents the 5th percentile, lower quartile, median, upper 425 
quartile, and 95th percentile values obtained from 1000 simulated data sets. *; p < 0.05; ***; p < 0.001, 426 
significantly different from the group with a CLCR of 120 mL/min by the Kruskal-waillis test following 427 
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by the Dunn test. †; p < 0.05;†††; p < 0.001, significantly different from the same CLCR without diarrhea 428 
by the Kruskal-waillis test following by the Dunn test.  429 
 430 
Fig. 6 Simulation for the effects of serum albumin (A and B) and C-reactive protein (CRP) (C and D) on 431 
the pharmacokinetics and pharmacodynamics of MPA in typical patients based on the final population 432 
model. The dose of MMF was fixed to 500 mg every 8 h. (A) AUC0-8 of MPA; (B) AUEC0-8 of IMPDH 433 
activity; (C) the relationship between the MPA plasma concentration and IMPDH activity. The dotted, 434 
thin, and thick lines represent 0.1, 1.2, and 10 mg/dL of CRP, respectively. The vertical line represents 435 
the MPA concentration of 3.59 µg/mL (the population mean of IC50 in the case of CRP 1.2 mg/dL); (D) 436 
AUEC0-8 of IMPDH activity. Each box plot represents the 5th percentile, lower quartile, median, upper 437 
quartile, and 95th percentile values obtained from 1000 simulated data sets. ***; p < 0.001, significantly 438 
different from the group of 4.2 mg/dL of serum albumin by the Kruskal-waillis test following by the 439 
Dunn test. †††; p < 0.001, significantly different from the group of 0.1 mg/dL of CRP by the 440 
Kruskal-waillis test following by the Dunn test. 441 
